X4 PHARMACEUTICALS, INC Additional Paid in Capital, Common Stock
X4 PHARMACEUTICALS, INC (XFOR) had Additional Paid in Capital, Common Stock of $786.43 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-06
- 2026-06-30: Additional Paid in Capital, Common Stock $786.43M.
- 2026-03-31: Additional Paid in Capital, Common Stock $783.27M.
- 2025-12-31: Additional Paid in Capital, Common Stock $780.86M.
- 2025-09-30: Additional Paid in Capital, Common Stock $632.34M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $786.43M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $783.27M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $780.86M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $632.34M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $544.91M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $538.14M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $537.62M 10-K · filed 2026-03-17 | $537.46M 10-K · filed 2025-03-26 |
| 2024-09-30 | $535.10M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $533.28M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $530.69M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $528.96M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $526.32M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $523.96M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $452.43M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $450.79M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $409.53M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $356.21M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $354.64M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $347.37M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $321.44M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $319.92M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $318.01M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $267.08M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $265.59M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $263.31M 10-Q · filed 2020-08-04 | |
| 2020-03-31 | $262.08M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $261.37M 10-K · filed 2021-03-19 | |
| 2019-09-30 | $200.42M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $199.69M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $119.52M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $2.15M 10-K · filed 2020-03-12 | $156.63M 10-K · filed 2019-03-11 |
| 2018-09-30 | $153.67M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $152.60M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $151.40M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $150.83M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |